Effectiveness of Aligners Versus Rapid Maxillary Expansion

Sponsor
University of Turin, Italy (Other)
Overall Status
Completed
CT.gov ID
NCT04760535
Collaborator
(none)
40
1
2
27.6
1.5

Study Details

Study Description

Brief Summary

Aim of the study is to assess the effectiveness of Invisalign® First clear aligners compared to tooth-borne Hyrax-type maxillary expander on palatal morphology in growing subjects using 3D technology.

Condition or Disease Intervention/Treatment Phase
  • Device: Invisalign® First Phase I treatment (Align Technology, Inc., Santa Clara, CA, USA)
  • Device: Tooth-borne Hyrax-type maxillary expander
N/A

Detailed Description

Aim of the study is to assess the effectiveness of Invisalign® First clear aligners compared to tooth-borne Hyrax-type maxillary expander on palatal morphology in growing subjects using 3D technology. This two-arm parallel-group randomized prospective clinical trial will include patients with: indications for maxillary expansion treatment, age between 6 and 10 years old, mixed dentition, good standard of oral hygiene, good compliance during treatment as assessed by the practitioner. Patients will be assigned to one of two expansion methods (arm A: Invisalign® First clear aligners, arm B: tooth-borne Hyrax-type maxillary expander) according to a computer-generated randomization list shortly before the start of expansion Primary outcome measure will be the change in palatal morphology (palatal volume and surface area variations). Secondary outcomes will be: arch dimensions (upper inter-canine width, upper inter-molar width, anterior segment length, posterior segment length), complications, patients' satisfaction and periodontal health. Due to the nature of the intervention blinding will not be possible. Potential statistical differences between the two intervention groups will be evaluated.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Aligners Versus Rapid Maxillary Expansion on 3D Palatal Volume in Mixed Dentition Patients: a Randomized Controlled Trial
Actual Study Start Date :
Jan 15, 2019
Actual Primary Completion Date :
Oct 15, 2020
Actual Study Completion Date :
May 3, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm A: Invisalign® First clear aligners

The Invisalign® First aligners are fabricated in a multilayer aromatic thermoplastic polyurethane/co-polyester 0.75mm (.030")-thick with a fine 3D manufacturing process.

Device: Invisalign® First Phase I treatment (Align Technology, Inc., Santa Clara, CA, USA)
Subjects in this arm will be instructed to wear aligners 24h/day for entire duration of the therapy. They will be asked to remove their retainers only while eating, drinking (except water), or cleaning. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.

Active Comparator: Arm B: tooth-borne Hyrax-type maxillary expander

The Hyrax-type maxillary expander is a tooth-borne expansion appliance that is fixed to the upper second deciduous molars (or to the first permanent molars) using bands and includes a midline 12-mm self-locking screw (Forestadent, Pforzheim, Germany; 0.9 mm, complete turn). The expansion screw is connected to the conventional molar bands or printed clasps, modeled surrounding the molars, via a framework of 0.9mm stainless-steel wire. The framework is soldered to the bands and extending on the palatal side to the deciduous canines. The expander will be fabricated by qualified laboratory technician.

Device: Tooth-borne Hyrax-type maxillary expander
The expansion protocol was one quarter-turn twice a day (0.45 mm activation per day) until overcorrection with the maxillary lingual cusps contacting the mandibular buccal cusps. The expander was left passively for retention for a minimum of 6 months. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.

Outcome Measures

Primary Outcome Measures

  1. Palate morphology [12 months]

    The primary outcome will be to evaluate the changes in palatal morphology after the treatment of maxillary deficiencies using two different therapies and to re-evaluate changes over the initial 12-months after the end of the treatment. The changes in palatal morphology are defined as the variation in palatal volume and surface. These will be measured from digitized study models within the boundaries of the palate, the gingival and distal planes, defined as follow. The gingival plane will be created by connecting the midpoints of the dentogingival junction of all upper erupted deciduous and permanent teeth. The distal plane will be created through two points at the distal of the first upper permanent molars perpendicular to the gingival plane.

Secondary Outcome Measures

  1. Upper inter-canine width (ICW) [12 months]

    Upper inter-canine width (ICW) (secondary outcome measure) is the transverse distance between upper canines in millimeters.

  2. Upper inter-molar width (IMW) [12 months]

    Upper inter-molar width (IMW) (secondary outcome measure) is the transverse distance between upper first molars in millimeters.

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 10 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients who have been diagnosed with transverse maxillary deficiency;

  • mixed dentition phase with cervical vertebral maturation stage (CVMS) less than 4;

  • fully erupted upper and lower first molars;

  • transversal discrepancy ≤5mm

  • demonstration of a good standard of oral hygiene (determined through questioning and clinical examination);

  • subjects willing to consent to the trial and comply with the trial regime.

Exclusion Criteria:
  • any general medical health problems which may influence gingival health, such as those necessitating antibiotic cover as bacteremia prophylaxis, diabetes mellitus, epilepsy, or physical or mental disability;

  • permanent teeth extraction-based treatment (third molars excluded);

  • morphologic crown anomalies;

  • auxiliary treatment during arch expansion stage (such as crossbite elastics);

  • posterior interproximal reduction;

  • orthognathic surgery treatment planned;

  • cleft palate or severe facial deformities.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Turin Turin Italy 10126

Sponsors and Collaborators

  • University of Turin, Italy

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tommaso Castroflorio, Aggregate Professor of Orthodontics, University of Turin, Italy
ClinicalTrials.gov Identifier:
NCT04760535
Other Study ID Numbers:
  • Maxillary Expansion
First Posted:
Feb 18, 2021
Last Update Posted:
May 25, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No

Study Results

No Results Posted as of May 25, 2022